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Abstract
Distinct phylogenetic lineages of Mycobacterium tuberculosis (MTB) cause disease in patients of particular genetic ancestry,
and elicit different patterns of cytokine and chemokine secretion when cultured with human macrophages in vitro.
Circulating and antigen-stimulated concentrations of these inflammatory mediators might therefore be expected to vary
significantly between tuberculosis patients of different ethnic origin. Studies to characterise such variation, and to
determine whether it relates to host or bacillary factors, have not been conducted. We therefore compared circulating and
antigen-stimulated concentrations of 43 inflammatory mediators and 14 haematological parameters (inflammatory profile)
in 45 pulmonary tuberculosis patients of African ancestry vs. 83 patients of Eurasian ancestry in London, UK, and
investigated the influence of bacillary and host genotype on these profiles. Despite having similar demographic and clinical
characteristics, patients of differing ancestry exhibited distinct inflammatory profiles at presentation: those of African
ancestry had lower neutrophil counts, lower serum concentrations of CCL2, CCL11 and vitamin D binding protein (DBP) but
higher serum CCL5 concentrations and higher antigen-stimulated IL-1 receptor antagonist and IL-12 secretion. These
differences associated with ethnic variation in host DBP genotype, but not with ethnic variation in MTB strain. Ethnic
differences in inflammatory profile became more marked following initiation of antimicrobial therapy, and immunological
correlates of speed of elimination of MTB from the sputum differed between patients of African vs. Eurasian ancestry. Our
study demonstrates a hitherto unappreciated degree of ethnic heterogeneity in inflammatory profile in tuberculosis
patients that associates primarily with ethnic variation in host, rather than bacillary, genotype. Candidate immunodiagnos-
tics and immunological biomarkers of response to antimicrobial therapy should be derived and validated in tuberculosis
patients of different ethnic origin.
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Introduction
Mycobacterium tuberculosis (MTB), the causative agent of tubercu-
losis (TB), emerged as a pathogen in Africa and has co-evolved
with humans following migration to Europe and Asia some 70,000
years ago [1]. Distinct phylogenetic lineages of MTB consistently
associate with human populations of different genetic ancestry in a
variety of settings [2–5] and elicit differing immune responses from
antigen-presenting cells of healthy donors in vitro [6–11]. Anti-
mycobacterial immune responses might therefore be expected to
vary between TB patients of different ethnic origin; however,
studies investigating this question have not been conducted.
Demonstration of significant ethnic variation in inflammatory
responses at presentation and after initiation of treatment would
have implications for the development of immunodiagnostics and
for the identification of surrogate endpoints for trials of
antituberculous drugs.
We therefore conducted a study to characterise ethnic variation
in circulating and antigen-stimulated concentrations of a panel of
43 soluble inflammatory mediators and 14 haematological
parameters (collectively termed ‘inflammatory profile’) before
and after intensive-phase antituberculous therapy in a multi-
ethnic cohort of patients with pulmonary tuberculosis (PTB) who
participated in a clinical trial of adjunctive vitamin D supplemen-
tation conducted in London, UK [12]. The primary comparison
was between patients of African vs. Eurasian ancestry, on the
grounds of the distinct genetic structure of these populations [13],
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and because TB patients of African ancestry are recognised to
have delayed clearance of MTB from the sputum in comparison to
non-African patients [14,15] – a phenomenon that might be
immunologically mediated_ENREF_17. We found that patients of
African and Eurasian ancestry had significantly different inflam-
matory profiles at presentation, and that these differences
associated primarily with variation in host, but not bacillary,
genotype. Ethnic differences in inflammatory profile became more
marked after intensive-phase treatment, and immunological
correlates of time to sputum culture conversion between patients
of African vs. Eurasian ancestry were distinct.
Results
PTB patients of African vs. Eurasian ancestry have distinct
inflammatory profiles at presentation
A total of 141 patients were eligible to participate in the study
(Study Profile, Figure S1). Self-defined ethnic origin was used to
attribute ancestry as African (n= 45), Eurasian (n = 83), East Asian
(n = 9), Latin American (n= 3) or mixed (n= 1) according to
Rosenberg’s five-region classification [13]. Due to small numbers
in other groups, analyses were confined to participants of African
and Eurasian ancestry. These two groups had similar demographic
and clinical characteristics at presentation, the only statistically
significant difference being a slightly shorter duration of symptoms
pre-diagnosis in patients of African vs. Eurasian ancestry (median
2.0 vs. 2.5 months respectively, p = 0.03; Table 1).
Forty-three soluble factors and 14 haematological parameters
detailed in Table S1 were measured in samples of serum, plasma
or whole blood taken at baseline. The median circulating
concentrations of 7 soluble factors (Interleukin [IL]-2, IL-5, IL-
13, IL-17, tumour necrosis factor [TNF], basic fibroblast growth
factor [FGF-b] and matrix metalloproteinase-7 [MMP-7]) were
below the limit of detection (LOD) at baseline and were excluded
from further analyses; median values, ranges and LODs for these
analytes at baseline are presented in Table S2.
The remaining 50 parameters were then analysed using the t-
test for general linear models (GLM) with statistical adjustment for
covariates with potential to influence inflammatory profile (age,
sex, duration of symptoms pre-diagnosis, duration of antimicrobial
therapy pre-sampling and baseline serum 25-hydroxyvitamin D
[25(OH)D] concentration). Five parameters were identified as
having concentrations which were significantly different (false
discovery rate [q-value]#0.05) between participants of African vs.
Eurasian ancestry. Four (peripheral blood neutrophil count and
serum concentrations of CC chemokine ligand [CCL] 2, CCL11
and vitamin D binding protein [DBP]) were lower in participants
of African vs. Eurasian ancestry (p#0.0018), and one (serum
CCL5 concentration) was higher (p = 2.1561025; Table 2;
Figure 1). These parameters were then assessed using principal
component analysis (PCA), a well-established mathematical
technique for reducing the dimensionality of complex datasets
by transforming the data to a new coordinate system [16]. This
provided a visual representation of how well the identified
parameters differentiated individuals from the two ethnic groups
(Figure 2).
Despite the relative homogeneity in genetic structure in
populations of Asian and European ancestry [13], healthy Asians
and Europeans have previously been reported to have differing
inflammatory profiles that associate with increased risk of coronary
heart disease [17]. In order to explore whether combining these
groups concealed significant heterogeneity in inflammatory profile
in patients with TB, we stratified the analysis above, subdividing
the Eurasian group into European and Middle Eastern vs. Central
and South Asian. The resultant PCA plot showed that inflamma-
tory profiles of these two groups clustered together, and were
separated from those of patients of African ancestry (Figure 2). In
keeping with this observation, no significant differences in
circulating concentrations of inflammatory mediators were found
between Eurasian sub-groups (Figure 3). Our decision to combine
data for Europeans and Asians in subsequent analyses was further
justified by the finding that allele frequencies of two single
nucleotide polymorphisms investigated in the DBP gene (rs 4588
and rs 7041) did not differ between participants of European/
Middle Eastern vs. Central/South Asian ancestry (p$0.32), but
that they were different between Eurasians and Africans (p,0.001,
Table 1)
In order to determine whether antigen-stimulated responses also
differed between patients of African vs. Eurasian ancestry, whole
blood samples taken from a sub-group of 42 patients (13 of African
ancestry, and 29 of Eurasian ancestry) were stimulated ex vivo with
the recombinant MTB antigen culture filtrate protein, 10 kDa
(rCFP-10). The concentrations of 39 soluble factors listed in Table
S1 were assayed in supernatants of whole blood samples taken at
baseline and stimulated with rCFP-10 for 72 hours. The median
concentrations of six soluble factors (IL-2, IL-5, IL-13, epidermal
growth factor [EGF], FGF-b and MMP-7) were below the LOD at
baseline and were excluded from further analyses; median values,
ranges and LODs for these analytes are presented in Table S2.
The remaining 33 parameters were analysed using the t-test for
GLM with the same adjustment for covariates as conducted for
circulating responses. Those that were different between groups
were visualised by PCA. Two such parameters were found:
antigen-stimulated concentrations of IL-1 receptor antagonist [IL-
1RA] and IL-12 were both higher in participants of African vs.
Eurasian ancestry (p#0.0030; Table 2; Figure 1). As before, we
conducted a sensitivity analysis to determine whether patients of
European/Middle Eastern vs. Central/South Asian ancestry
differed in their antigen-stimulated inflammatory profile: both
the PCA plot (Figure 2) and scatter plots (Figure 3) showed similar
Author Summary
Mycobacterium tuberculosis (MTB) is the causative agent of
tuberculosis. Genetically distinct strains of MTB cause
disease in particular ethnic groups, and these strains vary
in their ability to elicit inflammatory responses from
antigen-presenting cells in vitro. Circulating and antigen-
stimulated concentrations of inflammatory mediators
(‘inflammatory profile’) might therefore be expected to
differ between tuberculosis patients of different ethnic
origin; however, this question has not previously been
addressed. We therefore conducted a study to characterise
ethnic variation in inflammatory profiles in a cohort of 128
newly-diagnosed tuberculosis patients in London, UK.
Patients of African vs. Eurasian ancestry had distinct
inflammatory profiles at presentation; differences did not
relate to MTB strain variation between groups, but they
did associate with ethnic variation in host genotype.
Moreover, immunological correlates of the rate of MTB
clearance from sputum differed between patients of
African vs. Eurasian ancestry. Our findings provide insight
into the mechanisms underlying ethnic variation in
inflammatory profile in tuberculosis patients, and indicate
that candidate immunodiagnostics and immunological
biomarkers of response to tuberculosis therapy should be
derived and validated in tuberculosis patients of different
ethnic origin.
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patterns between these sub-groups. Moreover, conducting a t-test
for GLM analysis did not identify any significant differences in
inflammatory profile between the Eurasian sub-groups, further
strengthening the rationale to pool data for patients of European/
Middle Eastern and Central/South Asian ancestry together in
subsequent analyses.
Ethnic variation in inflammatory profile is not explained
by variation in MTB strain lineage
MTB has co-evolved with humans, and different bacillary
strains associate with different ethnic groups [2]; moreover, MTB
strains of different lineage elicit differing immune responses in vitro
[6–11] _ENREF_8. Ethnic variation in inflammatory profile in
PTB might therefore be explained by differential representation of
MTB strain lineages between ethnic groups. To investigate this
possibility, genetic lineages of isolates from sputum of study
participants were determined using multilocus Mycobacterial
Interspersed Repetitive Units – Variable Number of Tandem
Repeats (MIRU-VNTR) analysis [18], and frequencies of isolates
of different lineage were compared between patient groups.
Isolates of Indo-Oceanic (Lineage 1), East Asian (Lineage 2) and
East African-Indian (Lineage 3) lineages tended to be under-
Table 1. Baseline characteristics of tuberculosis patients of African vs. Eurasian ancestry.
African ancestry (n=45) Eurasian ancestry (n =83) p
Median age, years (IQR) 29.3 (23.7 to 38.2) 30.8 (24.8 to 41.0) 0.43
Sex
Male 31 (69) 65 (78) 0.24
Female 14 (31) 18 (22)
BMI, kg/m2 19.9 (2.6) 20.1 (3.1) 0.73
Educated beyond 18 years 25 (56) 35 (42) 0.15
In UK before age 18 years 19 (42) 28 (34) 0.35
Occupation
Student 9 (20) 9 (11) 0.28
Employed 32 (71) 62 (75)
Unemployed 4 (9) 12 (14)
Diabetes mellitus 2 (4) 5 (6) .0.99
Median duration of symptoms pre-diagnosis, months (IQR) 2.0 (1.0 to 3.0) 2.5 (1.5 to 4.0) 0.03
Median duration of treatment pre-enrolment, days (IQR) 2.0 (0.0 to 4.0) 2.0 (0.0 to 3.0) 0.70
Baseline sputum smearA
#3 AFB per high-power field 22 (49) 37 (45) 0.73
.3 AFB per high-power field 23 (51) 44 (53)
Median serum 25(OH)D, nmol/L (IQR) 18.0 (10.0 to 26.0) 16.0 (11.0 to 25.0) 0.73
Baseline chest radiograph
Cavities present 22 (49) 47 (57) 0.40
Median no. zones affected, IQR 2.5 (2.0 to 4.0) 3.0 (2.0 to 4.0) 0.83
DBP genotype
Gc1F/1F 22 (49) 5 (6) ,0.001
Gc1F/2 8 (18) 12 (14)
Gc2/2 0 (0) 4 (5)
Gc1F/1S 9 (20) 14 (17)
Gc2/1S 1 (2) 27 (33)
Gc1S/1S 5 (11) 21 (25)
M. tuberculosis antimicrobial sensitivity
Isoniazid-sensitive 43 (96) 72 (87) 0.14
Isoniazid-resistant 2 (4) 11 (13)
M. tuberculosis strain lineageB
Indo-Oceanic lineage 3 (7) 10 (12) 0.08
East Asian lineage 0 (0) 6 (7)
East African-Indian lineage 12 (27) 27 (33)
Euro-American lineage 29 (64) 39 (47)
West African lineages 1 (2) 0 (0)
Data are number (%) or mean (standard deviation) except where stated. IQR, inter-quartile range; BMI, body mass index; AFB, acid-fast bacilli. DBP, vitamin D binding
protein; A, Baseline sputum smear result unavailable for 2 Eurasian participants; B, M. tuberculosis genotype unavailable for one Eurasian participant.
doi:10.1371/journal.ppat.1003468.t001
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represented, and isolates of Euro-American (Lineage 4) lineage
over-represented, in participants of African vs. Eurasian ancestry
(Table 1; p = 0.08). We therefore repeated the analyses of ethnic
differences in inflammatory profile above, including additional
statistical adjustment for MTB strain lineage: the set of parameters
identified as being significantly different between patients of
African vs. Eurasian ancestry was unchanged (Table 2), suggesting
that MTB strain lineage was not a determinant of ethnic
differences in inflammatory profile that we had observed.
As a further test of the influence of MTB strain lineage on
immune responses in the host, we conducted stratified analyses to
compare inflammatory profiles associated with different MTB strain
lineages in patients of African and Eurasian ancestry separately.
Among patients of Eurasian ancestry, no statistically significant
differences in either circulating or antigen-stimulated immune
responses were observed between patients infected with organisms
of different strain lineage. Among patients of African ancestry,
serum concentrations of prostaglandin E2 (PGE2) were significantly
Figure 1. Ethnic variation in inflammatory profile in PTB before and after intensive-phase antituberculous therapy. At diagnosis,
patients of African ancestry had lower neutrophil counts (A), lower serum concentrations of CCL2 (B), CCL11 (C) and DBP (D), but higher serum
concentrations of CCL5 (E) and higher antigen-stimulated IL-1RA and IL-12 (F,G) than those of Eurasian ancestry (p#0.0030). These differences
persisted after completion of intensive-phase antimicrobial therapy for all circulating parameters illustrated (A–E; p#7.8461026). 8-week antigen-
stimulated CCL11 concentrations were also lower in patients of African vs. Eurasian ancestry (H; p = 6.4561029). P-values were derived from the t-test
for general linear models, separately applied to baseline and 8-week samples, with adjustment for the following covariates: age, sex, months of
symptoms pre-diagnosis, duration of antimicrobial therapy pre-sampling and either baseline vitamin D status (baseline samples) or isoniazid
sensitivity and allocation to vitamin D vs. placebo (8-week samples). P-values are only indicated for parameters with a false discovery rate (q-
value)#0.05, as determined by the Benjamini Hochberg approach. *** p,0.001, ** p= 0.001 to ,0.01. Lines at median. LOD, limit of detection.
doi:10.1371/journal.ppat.1003468.g001
Figure 2. Principal component analysis (PCA) plots generated using immunological parameters which contribute to variation in
baseline inflammatory profile between PTB patients of African and Eurasian ancestry. Each point represents one patient, and its position
in the plot is determined by the combined effects of all parameters measured for that patient sample that contribute significantly to ethnic variation
in inflammatory profile. The distance between sample points represents Euclidean distance. The first 3 component vectors are displayed, along with a
% figure signifying the proportion of the variability in the data that each component accounts for. Points representing patients with Eurasian ancestry
have been coloured according to their ethnic subgroup (Central/South Asian (blue) and European/Middle Eastern (yellow) ancestry) to demonstrate
that they cluster together and that they are separated from those representing patients of African ancestry (black). One patient of mixed South Asian
and European ancestry is classified as a Eurasian (green) and clusters within samples from the Eurasian subgroups. A, PCA plot of circulating
immunological parameters in patients of African (n = 45), Central/South Asian (n = 55), European/Middle Eastern (n = 27) and Eurasian (n = 1) ancestry
at baseline. B, PCA plot of rCFP-10-stimulated immunological parameters in patients of African (n = 13), Central/South Asian (n = 22) and European/
Middle Eastern (n = 7) ancestry at baseline.
doi:10.1371/journal.ppat.1003468.g002
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lower in patients infected with MTB of East African-Indian lineage
compared to those infected by other lineages (p= 0.0008; Figure 4),
but no inter-lineage differences were seen for any other circulating
parameter, or for any antigen-stimulated parameter investigated.
Ethnic variation in host DBP genotype relates to ethnic
differences in inflammatory profile
Since ethnic variation in the distribution of MTB strain lineages
did not associate with differences in inflammatory profile observed
between participants of African vs. Eurasian ancestry, we
proceeded to investigate whether these differences might arise as
a result of genetic variation in the host – a hypothesis suggested by
results of human genome scans identifying chromosomal regions
that influence immune responses to M. tuberculosis [19,20]. To
explore this possibility, we investigated two common functional
single nucleotide polymorphisms in the DBP gene (rs4588 and
rs7041), combinations of which form three haplotypes (Gc1F,
Gc1S and Gc2). These polymorphisms were selected for investi-
gation on the basis that they have been shown to influence
antimycobacterial immune responses; that their frequency varies
between people of African vs. Eurasian ancestry [21]; and that we
had identified a significant difference in DBP concentration
Figure 3. Inflammatory profiles of PTB patients of European/Middle Eastern and Central/South Asian ancestry are similar to each
other, and different from those of patients of African ancestry. No statistically significant differences in neutrophil count (A), serum
concentrations of CCL2 (B), CCL5 (C), CCL11 (D), CXCL8 (E), vitamin D binding protein (DBP) (F) or antigen-stimulated concentrations of CCL11 (G), IL1-
RA (H) or IL-12 (I) were seen at baseline or at 8 weeks in PTB patients of European/Middle Eastern vs. Central/South Asian ancestry. However, when
pooled data from patients of Eurasian ancestry were compared with those of patients of African ancestry, baseline differences attained statistical
significance for all parameters except serum CXCL8 concentration (E) and antigen-stimulated CCL11 (G), and 8-week differences attained statistical
significance for all parameters except antigen-stimulated IL1-RA (H) and IL-12 (I). P-values were derived from the t-test for general linear models,
separately applied to baseline and 8-week samples, with adjustment for the following covariates: age, sex, months of symptoms pre-diagnosis,
duration of antimicrobial therapy pre-sampling and either baseline vitamin D status (baseline samples) or isoniazid sensitivity and allocation to
vitamin D vs. placebo (8-week samples). Parameters with a false discovery rate (q-value).0.05, determined by the Benjamini Hochberg approach,
were designated non-significant (ns). ***, p,0.001; **, p = 0.001 to ,0.01. Lines at median. LOD, limit of detection. Afr, African ancestry; Eur,
European/Middle Eastern ancestry; As, Central/South Asian ancestry.
doi:10.1371/journal.ppat.1003468.g003
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between ethnic groups. Rs4588 and rs7041 genotypes were
determined, and haplotype frequencies were compared between
ethnic groups: Gc1F carriers were over-represented, and Gc2
carriers under-represented, in patients of African vs. Eurasian
ancestry (p,0.0001, Table 1). Moreover, serum DBP concentra-
tion in newly-diagnosed TB patients varied with DBP genotype,
with those of Gc1F/1F genotype having the lowest concentrations
and those with Gc1S/1S genotype having the highest concentra-
tions, irrespective of ethnic group (p,0.0001 for comparison by
genotype; p.0.05 for ethnic comparison within each genotype;
Figure 5).
We therefore repeated the analysis of ethnic differences in
inflammatory profiles, this time including statistical adjustment
for DBP genotype in addition to the phenotypic characteristics
previously incorporated in the model. Ethnic differences in
neutrophil count, in serum DBP concentration, and in antigen-
stimulated responses that had previously attained statistical
significance in the original model were rendered non-signifi-
cant by this adjustment (Table 2). The effect of the adjustment
for DBP genotype is further illustrated in Figure 6, which shows
a reduction in separation of samples from patients of African
vs. Eurasian ancestry in a PCA plot after incorporation of DBP
genotype in the model. We conclude that ethnic variation in
DBP genotype associates with variation in inflammatory
profiles observed between PTB patients of African vs. Eurasian
ancestry.
Ethnic variation in inflammatory profiles persists after
completion of intensive-phase antituberculous therapy
We next proceeded to investigate whether ethnic differences in
inflammatory profiles persisted after completion of intensive-phase
antituberculous therapy. Concentrations of the same immunolog-
ical parameters described above were assayed in samples of serum,
plasma and whole blood taken after 8 weeks of antituberculous
therapy from a cohort of 85 patients (30 of African ancestry and 55
of Eurasian ancestry) who fulfilled pre-defined criteria for inclusion
in the per-protocol analysis of the clinical trial in which they were
participating (Study Profile, Figure S1). Patients of different ethnic
origin whose samples contributed to this analysis had similar
demographic and clinical characteristics, the only statistically
significant difference being a shorter duration of symptoms pre-
diagnosis in patients of African vs. Eurasian ancestry (median 1.9
vs. 3.0 months respectively, p = 0.001). As before, parameters
whose concentration was significantly different between partici-
pants of African vs. Eurasian ancestry were identified using the t-
test for GLM, with adjustment for clinical and demographic
Figure 4. Baseline serum prostaglandin E2 (PGE2) concentra-
tion varies between PTB patients of African ancestry infected
with different MTB strain lineages. Patients infected with isolates
of East African-Indian lineage had lower PGE2 concentrations compared
to those infected with isolates from other lineages (p = 0.0008,
q = 0.0411). P-values were derived from the F-test for GLM, with
adjustment for the following covariates: age, sex, months of symptoms
pre-diagnosis, duration of antimicrobial therapy pre-sampling and
baseline vitamin D status, with the false discovery rate (q-value)
determined by the Benjamini Hochberg approach; Lines at median.
doi:10.1371/journal.ppat.1003468.g004
Figure 5. Serum vitamin D binding protein (DBP) concentration in patients with newly-diagnosed PTB by DBP genotype and ethnic
group. DBP concentration varied with DBP genotype, with patients of Gc1F/1F genotype having the lowest concentrations, and those with Gc1S/1S
genotype having the highest concentrations, irrespective of ethnic group (p,0.0001 for comparison by genotype with ethnic groups pooled; p.0.05
for ethnic comparison within each genotype). Kruskal-Wallis test with Dunn’s multiple comparison test. AFR, African ancestry; EUA, Eurasian ancestry.
doi:10.1371/journal.ppat.1003468.g005
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covariates with potential to influence the effects of antimicrobial
therapy on immune responses (age, sex, duration of symptoms pre-
diagnosis, duration of antimicrobial therapy pre-sampling, isoni-
azid sensitivity vs. resistance, and allocation to vitamin D vs.
placebo in trial). The effect of significant parameters was then
assessed visually using PCA.
This analysis revealed that ethnic differences in neutrophil
count and serum concentrations of CCL2, CCL5, CCL11 and
DBP persisted at 8 weeks (p#7.8461026, Figure 1) and that an
additional parameter, serum C-X-C chemokine ligand 8 (CXCL8)
concentration, was lower in participants of African vs. Eurasian
ancestry at this time point (p = 0.0018; Table 2). PCA plots of
circulating inflammatory parameters sampled at different time
points show that samples from patients of African vs. Eurasian
ancestry were more widely separated at 8 weeks compared to
baseline (Figure 6), indicating that ethnic variation in circulating
inflammatory profile was more marked at 8 weeks than at baseline.
Ethnic variation in antigen-stimulated responses was also observed
in 8-week samples, with supernatant concentrations of antigen-
stimulated CCL11 and hepatic growth factor (HGF) being
significantly lower in patients of African vs. Eurasian ancestry
after completion of intensive-phase therapy (p#0.0023; Table 2,
Figure 1).
As an additional check to determine whether any of this
variation could be attributed to the effects of adjunctive vitamin D
supplementation, which we have previously shown to be
immunomodulatory [22], we repeated the analyses above in the
sub-group of 47 participants allocated to the placebo arm of the
clinical trial in which they were participating. Near-identical
results were obtained in this smaller cohort (Table S4, Figure S2),
confirming that ethnic differences in 8-week inflammatory profile
observed in the analysis of all participants did not arise as a result
of confounding by differential allocation to vitamin D vs. placebo
in patients of African vs. Eurasian ancestry.
Figure 6. Ethnic variation in circulating inflammatory responses in PTB is reduced by adjustment for host vitamin D binding
protein (DBP) genotype, but accentuated by administration of intensive-phase antimicrobial therapy. Principal component analysis
(PCA) plots generated using circulating parameters which contribute to ethnic variation in inflammatory profile in patients with PTB are displayed.
Each point represents one patient, and its position in the plot is determined by the combined effects of all circulating parameters measured for that
patient sample contributing significantly to ethnic variation in inflammatory profile. The distance between sample points represents Euclidean
distance. The first 3 component vectors are displayed, along with a % figure signifying the proportion of the variability in the data that each
component accounts for. A, PCA plot of circulating immunological parameters in patients of African (black, n = 45) vs. Eurasian (green, n = 83) ancestry
at baseline. B, PCA plot as for A, but with additional statistical adjustment for host DBP genotype; separation of samples from patients of African vs.
Eurasian ancestry is reduced as compared with panel A, indicating that DBP genotype accounts for a significant degree of ethnic variation in baseline
inflammatory profile. C, PCA plot of circulating immunological parameters after intensive phase antimicrobial therapy; separation of samples from
patients of African vs. Eurasian ancestry is increased as compared with panel A, indicating that ethnic differences in inflammatory profile become
more marked following two months of treatment.
doi:10.1371/journal.ppat.1003468.g006
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Ethnic variation in inflammatory profiles associated with
fast vs. slow response to antituberculous therapy
Given that differences in immune response have been
reported to associate with differences in microbiological
clearance among patients with PTB [23–25], and that speed
of sputum culture conversion has been reported to vary
between TB patients of African vs. Eurasian ancestry [14,15]
we wished to determine whether ethnic differences in
inflammatory response associated with variation in microbio-
logical response to therapy. To this end, we compared time to
sputum culture conversion between participants of African vs.
Eurasian ancestry in our cohort, and found no significant
difference (p = 0.41). Since ethnic differences in inflammatory
profile persisted throughout intensive-phase treatment, we
reasoned that profiles associated with fast vs. slow sputum
culture conversion might therefore differ between ethnic
groups. To test this hypothesis, we classified each participant
for whom sputum culture conversion data were available
(n = 82) according to their time to sputum culture conversion
from positive to negative, denoting those with time greater
than or equal to the median value of 37.25 days ‘slow
converters’ (n = 41), and those with time less than this value
‘fast converters’ (n = 41). Clinical characteristics of patients
having fast vs. slow sputum culture conversion, stratified by
ethnicity, are compared in Table S3. Slow sputum culture
conversion was associated with older age and higher baseline
sputum bacillary load among Eurasians (p#0.01); similar
trends were seen among Africans (p#0.45). We then compared
inflammatory profiles measured during the course of intensive-
phase therapy between fast and slow sputum culture converters
for patients of African vs. Eurasian ancestry. The interaction
analysis for ethnic group was conducted using rank regression
on the interaction term ‘week of sampling*speed of sputum
culture conversion’ with adjustment for the same covariates as
for the analysis of 8-week samples above, plus week of sampling
and subject ID. Baseline bacillary load was not adjusted for as
this is likely to be a significant driver of differences in
inflammatory profiles between fast vs. slow converters.
The kinetics of circulating inflammatory responses differed
markedly between patients with fast vs. slow sputum culture
conversion, and immunological correlates of speed of sputum
culture conversion differed between patients of African vs.
Eurasian ancestry. Circulating immunological correlates of fast
vs. slow sputum culture conversion in patients of African vs.
Eurasian origin are summarised schematically in Figure 7, and
presented in detail in Table 3 and Figure 8. Of the 50 parameters
investigated, 27 were associated with speed of sputum culture
conversion in one or both ethnic groups. Twelve of these
parameters associated with speed of sputum conversion in patients
Figure 7. Circulating immunological correlates of slow sputum culture conversion differ between PTB patients of African vs.
Eurasian ancestry. Upward arrows indicate parameters whose concentration was higher in patients with slow sputum culture conversion (defined
as time to sputum culture conversion $37.25 days), and downward arrows indicate parameters whose concentration was lower in these patients.
Only four of the 27 identified parameters have the same pattern of response in both ethnic groups.
doi:10.1371/journal.ppat.1003468.g007
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of Eurasian ancestry only; nine associated with speed of sputum
culture conversion in patients of African ancestry only; four
associated similarly with speed of response in both ethnic groups;
and two were differentially associated with speed of sputum culture
conversion in patients of African vs. Eurasian ancestry, i.e.
elevated levels of these markers associated with slower sputum
culture conversion in one ethnic group and faster conversion in
another.
As a further step to validate our findings, we applied
network PCA to the parameters listed in Table 3 in order to
investigate the relationship between changes in inflammatory
parameters observed during treatment (Figure 9). For both
ethnic groups, acute phase reactants erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP) were linked and
red cell parameters were linked to each other. In the African
network MMP-1 was linked to its inducer PGE2, and
chemokines CCL2 and CCL11 were closely linked, while in
the Eurasian network, monocyte and neutrophil counts were
closely linked. These linkages are consistent with biological
understanding of the regulation of these inflammatory
mediators and cell populations, validating results of the
PCA. Kinetics of antigen-stimulated responses were not
compared between groups due to small numbers within each
sub-group.
Figure 8. Circulating immunological correlates of time to sputum culture conversion in PTB patients of African vs. Eurasian
ancestry. Higher ESR and serum MMP-1 concentration associated with slower sputum culture conversion in patients of African and Eurasian ancestry
alike (A–B, p#0.0080). Higher red blood cell count and lower serum vitamin D binding protein concentration associated with slower sputum culture
conversion in patients of African ancestry but faster sputum culture conversion in those of Eurasian ancestry (C–D, p#0.0075). Lower serum
concentrations of CCL11 and IL-7 associated with slower sputum culture conversion in patients of African ancestry (p#0.0028), but did not associate
with treatment response in those of Eurasian ancestry (E–F). Higher plasma concentrations of cathelicidin LL-37 and lower serum concentration of
CXCL10 associated with slower sputum culture conversion in patients of Eurasian ancestry (p#4.98610205), but did not associate with treatment
response in those of African ancestry (G–H). Fast (solid lines) vs. slow (dashed lines) sputum clearance defined as time to sputum culture conversion
,37.25 days vs. $37.25 days, respectively. Means 6 SEM at 0, 2, 4, 6 and 8 weeks of treatment are presented. Data for all parameters except red
blood cell count were normalised by log10 transformation and the y-axis presented as 10‘(log value). P-values were generated using rank regression
with covariates on the interaction term ‘week of sampling*speed of sputum culture conversion, with adjustment for the following covariates: age,
sex, months of symptoms pre-diagnosis, duration of antimicrobial therapy pre-sampling, isoniazid sensitivity, allocation to vitamin D vs. placebo,
week of sampling and subject ID. Parameters with a false discovery rate (q-value).0.05, determined by the Benjamini Hochberg approach, were
designated non-significant (ns).
doi:10.1371/journal.ppat.1003468.g008
Ethnic Variation in Inflammation in Tuberculosis
PLOS Pathogens | www.plospathogens.org 10 July 2013 | Volume 9 | Issue 7 | e1003468
Discussion
Clinically significant ethnic differences in immune responses to
Plasmodium falciparum and human immunodeficiency virus have
previously been described [26,27], but to our knowledge, this
study is the first to address the question of whether inflammatory
responses vary between TB patients of different ethnic origin. We
report that inflammatory profiles vary significantly between TB
patients of African and Eurasian ancestry having similar clinical
and demographic characteristics, and that these differences
associate primarily with ethnic variation in host rather than
bacillary genotype. We also show that ethnic differences in
inflammatory profiles observed at presentation persist after
completion of intensive-phase therapy, and that immunological
correlates of speed of sputum bacillary clearance differ markedly
between patients of African vs. Eurasian ancestry. These findings
have important implications for the design of studies investigating
immunological biomarkers of response to antituberculous therapy.
African patients living in Africa have previously been reported
to have more extensive disease at diagnosis than Europeans living
in Europe, and to have lower rates of sputum conversion after
intensive-phase antimicrobial therapy [14,15], but controversy
remains as to whether this reflects ethnic variation in host-
pathogen interactions or geographical variation in laboratory
practice and/or access to effective therapy. In our study – where
patients of different ethnic origin were recruited in a single city,
and where all microbiological samples were analysed in a single
laboratory – we observed no difference in rates of cavitation or 2-
month sputum culture conversion between patients of African vs.
Eurasian ancestry. Despite this, we did observe significant ethnic
variation in inflammatory profile between groups. Many of these
differences were associated with variation in host DBP genotype,
supporting the findings of an in vitro study reporting that DBP has
broad influences on the antimycobacterial response [28]. This is
plausible, given that this protein modulates macrophage activation
and neutrophil chemotaxis, as well as performing its classical role
in transport of vitamin D metabolites in the circulation [29]. We
also observed ethnic variation in circulating and/or antigen-
stimulated concentrations of cytokines (IL-1RA, IL-12) and
chemokines (CCL2, CCL5, CCL11, CXCL8), many of which
play key roles in the antimycobacterial immune response. The
genes encoding these mediators are all polymorphic, and in some
cases, ethnic variation in frequency of alleles influencing anti-
mycobacterial responses has been reported [30,31]. Study of
functional associations of polymorphisms in these genes might
yield insights into the genetic basis for ethnic variation in immune
responses to MTB. Further investigation in other populations is
also required to validate the ethnic differences in inflammatory
profile that we report, as the large number of analyses and
relatively modest sample size of our study could have led to Type I
and Type II errors regarding specific parameters. Nevertheless,
our main conclusions regarding strong ethnic group differences
appear solid given the highly statistically significant differences
found after stringent adjustment for multiple comparisons.
In contrast to the variation in inflammatory response between
patients of different DBP genotype, relatively little difference in
circulating and antigen-stimulated responses was seen between
individuals infected with MTB strains of different lineage when
multivariate analysis of the full cohort of 128 patients was
performed. Secondary stratified analyses within the two main
ethnic groups were conducted as a ‘belt and braces’ validation, to
ensure that multivariate analysis had been successful in adjusting
for potential ethnicity-related confounders of the relationship
between MTB strain and immune profile. This secondary analysis
identified only one analyte which was affected by lineage, and only
in one ethnic group. The fact that the main analysis and the
validation analyses yielded the same result - i.e. minimal effect of
MTB strain on immune profile - lends considerable weight to our
Table 3. Circulating immunological correlates of speed of
sputum conversion in PTB patients of African vs. Eurasian
ancestry.
African (n =28) Eurasian (n =54)
tA pB tA pB
IL-1b 2.76 0.0067 - ns
IL-4 7.08 8.53610211 - ns
IL-6 - ns 4.08 6.09610205
IL-7 23.05 0.0028 - ns
IFN-a - ns 22.94 0.0036
CXCL10 - ns 24.13 4.98610205
CCL2 22.59 0.0108 - ns
CCL5 2.60 0.0105 - ns
CCL11 23.97 0.0001 - ns
VEGF - ns 3.34 0.0010
LL-37 - ns 4.70 4.33610206
MMP-1 2.86 0.0049 3.17 0.0017
MMP-2 - ns 22.76 0.0062
MMP-8 - ns 3.04 0.0026
PGE2 2.71 0.0077 3.03 0.0027
DBP 25.00 1.86610206 3.13 0.0019
Hb - ns 23.05 0.0026
MCV 24.39 2.34610205 - ns
PCV - ns 23.26 0.0013
MCH 25.20 7.62610207 - ns
MCHC 23.54 0.0006 - ns
RBC 3.00 0.0033 22.70 0.0075
Neutrophil count - ns 4.03 7.33610205
Monocyte count - ns 2.51 0.0127
Platelet count - ns 4.96 1.29610206
ESR 2.77 0.0064 2.67 0.0080
CRP 2.47 0.0149 4.62 6.18610206
A, t-statistic (regression co-efficient/standard deviation) represents magnitude
of difference in immunological parameter between patients with fast vs. slow
sputum culture conversion (,37.25 days vs. $37.25 days, respectively); a
negative t-statistic indicates a lower concentration of immunological parameter
in slower converters, and a positive t-statistic indicates a higher concentration
of immunological parameter in slower converters. B, p values derived using
rank regression with covariates on the interaction term ‘week of
sampling*speed of sputum culture conversion’ and adjusting for age, sex,
duration of symptoms pre-diagnosis, duration of antimicrobial therapy pre-
sampling, isolate sensitive vs. resistant to isoniazid, allocation to vitamin D vs.
placebo, week of sampling and subject ID. Parameters with a false discovery
rate (q-value).0.05, determined by the Benjamini Hochberg approach, were
designated non-significant (ns). For the purposes of applying this approach,
each ‘family’ of hypotheses corresponded to a single column of presented p
values.
IL, interleukin; IFN, interferon; CXCL, CXC chemokine ligand; CCL, CC chemokine
ligand; VEGF, vascular epidermal growth factor; LL-37, cathelicidin LL-37; MMP,
matrix metalloproteinase; PG, prostaglandin; DBP, vitamin D binding protein;
Hb, haemoglobin; MCV, mean corpuscular volume; PCV, packed cell volume;
MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin
concentration; RBC, red blood cell count; ESR, erythrocyte sedimentation rate;
CRP, C-reactive protein.
doi:10.1371/journal.ppat.1003468.t003
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conclusion that MTB strain is not a major determinant of immune
profile in tuberculosis.
This finding complements that of Pareek and colleagues, who
recently reported that ethnicity is a powerful determinant of
clinical TB phenotype independently of mycobacterial lineage
[32]. Other investigators have reported that ‘modern’ strains elicit
lower inflammatory responses than ‘ancient’ strains in macro-
phages, but that no difference in responses was seen in peripheral
blood leukocytes [11], the population of cells investigated here.
Further study is required to determine whether macrophages
isolated from TB patients of different ethnic origin vary in their
response to different MTB strains. Nevertheless, our observation
that ethnic differences in inflammatory profile persisted after the
several log-fold reduction in bacillary load induced by intensive-
phase therapy tends to support the hypothesis that host, rather
than bacillary, factors are the major determinants of ethnic
variation in inflammatory profile. Such variation in inflammatory
responses to antimicrobial treatment might reflect ethnic differ-
ences in allele frequency of polymorphisms of drug transporter
genes that have been shown to associate with pharmacokinetic
response to rifampicin [33]. However, our observations that
sputum conversion rates were similar in patients of African vs.
Eurasian ancestry, and that ethnic differences in inflammatory
responses post-therapy were qualitative rather than quantitative,
does not support this hypothesis. It is more plausible that, as at
baseline, ethnic differences in inflammatory profile after treatment
represent ethnic variation in alleles encoding components of the
inflammatory response. Such variation may have arisen as a result
of differences in selective pressures on the immune response
between populations that remained in Africa vs. those that
migrated out of the continent some 70,000 years ago [1].
Whatever the underlying reasons for these differences, our
observation that immunological correlates of fast vs. slow sputum
culture conversion differ between patients of African vs. Eurasian
ancestry has practical implications for the design of studies to
identify immunological correlates of response to intensive-phase
antituberculous therapy. Studies evaluating candidate biomarkers
published to date have been relatively small, and have tended to
investigate fewer parameters in smaller numbers of patients of
homogeneous ancestry than in the current study. Our finding that
high CRP and ESR associate with slow sputum culture conversion
is in keeping with other reports [25,34]. Larger studies are now
needed; our findings indicate that the validity of candidate
biomarkers of treatment response identified by such studies will
need to be evaluated in patients of different ancestry, as the
inflammatory response in TB is ethnically heterogeneous.
Materials and Methods
Participants
The patients included in this study were participants in the
AdjuVIT study - a double-blind randomised placebo-controlled
trial of high-dose vitamin D during intensive-phase antimicrobial
treatment of pulmonary TB, conducted in London, UK.
Recruitment commenced on January 25th 2007, and ended on
July 3rd 2009. A detailed account of study design has previously
been given [12]. Participants self-defined their ethnic origin using
the UK Office of National Statistics classification [35] and this
information was used to attribute ancestry into one of five groups:
African, Eurasian (incorporating participants of European, Middle
Eastern, Central or South Asian ethnic origin), East Asian,
Oceanic and American [13]. Baseline assessment included
collection of a sputum sample for microscopy and culture and a
blood sample. Fresh whole blood was sent for determination of full
blood count and ESR and ex vivo stimulation with a mycobacterial
antigen as described below. Aliquots of serum, plasma and whole
blood were also stored at 280uC until completion of the trial.
Participants were reviewed at 14, 28, 42 and 56 days after starting
antituberculous therapy to assess clinical status and to monitor for
adverse events. Blood and sputum samples were collected at each
time-point and processed as above. Full characterisation of
inflammatory profile was performed in the sub-set of participants
who fulfilled pre-defined criteria for per-protocol analysis (i.e.
Figure 9. Three-dimensional principal component analysis plots depicting the correlation network of analytes significantly
different between fast and slow culture converters of African and Eurasian ancestry during intensive phase anti-TB treatment. Plots
for patients of African and Eurasian ancestry are shown in panels A and B, respectively. Individual points represent a single analyte. The distance
between analytes is a measure of their Pearson correlation coefficients. Lines link analytes to their nearest neighbour, the analyte with the most
similar pattern of change during the course of treatment. Each analyte is coloured according to its R-statistic value, calculated by rank regression
interaction analysis. The concentration of analytes coloured blue is lower in patients with slow vs. fast sputum culture conversion, while the
concentration of those coloured yellow is higher in patients with slow vs. fast sputum culture conversion. Component vectors are displayed, along
with a % figure signifying the proportion of the variability in the data that each component accounts for.
doi:10.1371/journal.ppat.1003468.g009
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those infected with a rifampicin-sensitive isolate of M. tuberculosis
who received at least three doses of study preparation, who were
compliant with antituberculous therapy, who did not take second-
line antituberculous therapy or oral corticosteroids, who complet-
ed all study visits and who were not HIV sero-positive). The study
was approved by East London and The City Research Ethics
Committee (ref 06/Q0605/83), and registered with Clinical-
Trials.gov (NCT00419068). Written informed consent was
obtained from all participants before enrolment.
Antigen-stimulated whole blood assay (WBA)
For all participants recruited on or after May 15th 2008, fresh
whole blood was diluted 1:10 in RPMI 1640 medium (Sigma-
Aldrich, Gillingham, UK) and duplicate 180 ml aliquots were
stimulated in 96-well plates at 37uC in the presence of 5%CO2 with
rCFP-10 (Rv3874, Proteix Biotechnologies, Vestek, Czech Repub-
lic; final concentration 2.5 mg/ml) or 2% bovine serum albumin in
phosphate buffered saline (negative control). Plates were centrifuged
after 72 hours’ incubation, and cell-free supernatants were aspirated
and frozen at280uC pending immunological analysis. rCFP-10 was
tested for presence of endotoxin: concentration was found to be
260 IU (EU)/mg, working concentration 63 pg/ml. Addition of this
concentration of endotoxin to TB patients’ whole blood in control
experiments did not stimulate cytokine or chemokine secretion.
Immunological analysis
Immunological parameters were selected on the basis that they
played a role in host defence against MTB and/or that they were
recognised biomarkers of disease activity [36]. Concentrations of
43 soluble factors listed in Table S1 were determined in serum/
plasma as follows. Serum CRP and albumin concentrations were
assayed using an Architect ci8200 analyser (Abbott Diagnostics,
Chicago, IL, USA). Serum concentrations of IL-1b, IL-1RA, IL-
2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12 (p40/p70), IL-13,
IL-15, IL-17, G-CSF, GM-CSF, IFN-a, IFN-c, TNF, CXCL8,
CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11, EGF,
FGF-b, HGF and vascular endothelial growth factor (VEGF)
were quantified using a human 30-plex bead immunoassay panel
(sensitivity [sens.] according to Lot #617361, Invitrogen,
Camarillo, CA, USA). Serum samples required high dilution
for accurate determination of CCL5 concentration and all were
re-assayed using a single-plex bead assay (Invitrogen). Serum
PGE2 concentration was analysed by high sensitivity competitive
enzyme immunoassay (EIA; Assay Designs, Ann Arbo37.25r, MI,
USA; sens. 13.4 pg/ml). Plasma concentrations of antimicrobial
peptides (AMP) LL-37 (sens. 31 pg/ml), HNP1-3 (sens. 156 pg/
ml) and NGAL (sens. 400 pg/ml) were analysed by ELISA
(Hycult Biotechnology, Uden, The Netherlands). Plasma concen-
trations of MMP-1, -2, -3, -7 and -8 were determined by
Fluorokine MAP multianlalyte profiling (sens. according to Lot
#273379, R&D systems); plasma concentration of MMP-9 was
determined by DuoSet ELISA (sens. 3 pg/ml, R&D systems).
Serum concentration of DBP was determined by ELISA (sens.
0.65 ng/ml, R&D systems). Multi-plex bead assays were
performed on a Luminex 200 anlayzer (Luminex Corporation,
Austin, TX, USA). ELISA and EIA absorbances were measured
using a Benchmark Plus microplate spectrophotometer (Bio-Rad
Laboratories, Hertfordshire, UK). The concentrations of 39 of
these analytes (all of the above except DBP, PGE2, CRP and
albumin; listed in Table S1) were also determined in WBA
supernatants. Antigen-stimulated AMP and MMP concentrations
were corrected by subtraction of unstimulated values. For MMP-
2, -3, -8 and HNP and NGAL, unstimulated values were
generally greater than stimulated values and this was the case
sometimes for MMP-9 and LL-37. Cytokine/chemokine values
were generally undetectable in unstimulated samples and a
correction was not applied.
Fourteen haematological parameters listed in Table S1 were
also measured in fresh whole blood. Full blood counts were
performed using a LH750 haematology analyser (Beckman
Coulter, Brea, CA, USA). ESR was measured by the Wintrobe
method using a s2000 analyser (Desaga, Wiseloch, Germany).
DNA extraction and genotyping
Human DNA was extracted from whole blood using the
Promega Wizard SV 96 Genomic DNA Purification System on
the Biomek FX robot (Beckman Coulter), quantified using the
Nanodrop spectrophotometer and normalised to 5 ng/ml. 10 ng
DNA was used as template for 5 ml pre-developed TaqMan assays
(Applied Biosystems, Foster City, CA, USA) to type the StyI
(rs4588) and HaeIII (rs7041) polymorphisms of the vitamin D
binding protein. These assays were performed on the ABI
7900HT platform in 384-well format, and data were analysed
with Autocaller software. DBP haplotypes were deduced from StyI
and HaeIII genotypes as previously described [21]. Mycobacterial
DNA was extracted and genotyped using automated 15 myco-
bacterial interspersed repetitive unit–VNTR as previously de-
scribed [18].
Statistical analysis
Contingency tables were analysed using chi-square tests, unless
more than 20% of cells in a table had an expected frequency of
,5, when Fisher’s exact tests were employed. Median serum DBP
concentration was compared between groups using a Kruskal-
Wallis test with Dunn’s post hoc test to correct for multiple
comparisons. Time to sputum culture conversion was compared
between groups using a logrank test. Analyte concentrations were
calculated from raw luminex, ELISA and EIA data using
Masterplex ReaderFit software (Hitachi Solutions America, San
Francisco, CA, USA) and these calculated values were plotted
using GraphPad Prism 5 software (La Jolla, CA, USA). Linear
modelling and PCA was conducted using Qlucore Omics Explorer
2.2 software (Qlucore AB, Lund, Sweden). Analyte concentrations
were log2 converted and the variance was normalized to 1. For
analytes that were undetectable in at least one sample, the ‘limit of
detection’ value was added to every measured value for that
analyte prior to log2 conversion. Missing values were imputed by
K nearest neighbours (k-NN) [37]: for circulating parameters,
2.5% of data points were missing; for CFP-10-stimulated
parameters, 3% of data points were missing. Parameters whose
concentration differed significantly between patients of African vs.
Eurasian ancestry were identified using the t-test for GLM with
adjustment for covariates with potential to influence the inflam-
matory profile using the eliminated factors approach. This fits a
multiple regression model to all covariates, and subtracts the
expression values predicted by this model from the observed values
in order to remove covariate effects between patients [38]. An F-
test for GLM with adjustment for covariates with potential to
influence the inflammatory profile was performed to identify
parameters whose concentration varied according to MTB strain
lineage within each ethnic group. Parameters associating with slow
vs. fast sputum culture conversion within each ethnic group were
identified by rank regression analysis on the interaction term ‘week
of sampling*speed of sputum culture conversion’ with adjustment
for covariates with potential to influence the inflammatory profile,
week of sampling (to correct for effects of treatment duration
alone) and subject ID (to correct for repeated measures). Rank
regression was conducted by replacing the ordinal interaction
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categorical predictors with numerical predictors, followed by a
normal linear regression. Samples were ordered alternately fast,
then slow, with increasing time since treatment initiation [39].
These analyses yield t-statistics (calculated as the regression co-
efficient for each parameter divided by its standard deviation)
representing the magnitude of difference in concentration of a
given parameter between groups being compared; p values,
representing the probability that such differences could have arisen
by chance alone; and q values, which define the lowest false
discovery rate (FDR) for which the hypothesis would be accepted
under the Benjamini-Hochberg procedure for multiple testing
correction [40]. Thresholds of 0.05 were applied for p and q values
throughout.
PCA networks were created using one connection, i.e. by
connecting each analyte to the other analyte that it shares the most
similar pattern of change with over time; the distance between
analytes in the network represents their Pearson correlation
coefficients. Points in the network are coloured according to the
value of the R-statistic generated for each analyte from the rank
regression interaction analysis, which identified variables that had
a significantly different pattern of change between slow and fast
responders over time. The value of the R-statistic indicates the
proportion of the total variation of that variable which is explained
by the model tested. It is calculated as the square root of the R2-
statistic, and the sign indicates the direction of the observed effect.
A positive R-statistic indicates a higher concentration of that
analyte in slow vs. fast culture converters, and vice versa.
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Figure S1 Study profile.
(PPT)
Figure S2 Ethnic variation in inflammatory profile after
completion of intensive-phase antituberculous therapy:
participants allocated to placebo only. Patients of African
ancestry had lower neutrophil counts (A), lower serum concentra-
tions of CCL2, CCL11, CXCL8 and DBP (B–E) and lower levels
of antigen-simulated CCL11 (F), but higher serum concentrations
of CCL5 (G), than those of Eurasian ancestry. P-values were
derived from t-tests for general linear models applied to 8-week
placebo samples with adjustment for the following covariates: age,
sex, months of symptoms pre-diagnosis, duration of antimicrobial
therapy pre-sampling and isoniazid sensitivity. P-values are only
indicated for parameters with a false discovery rate (q-val-
ue)#0.05, as determined by the Benjamini Hochberg approach.
*** p,0.001, ** p = 0.001 to ,0.01. LOD, limit of detection.
Lines at median.
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Table S2 Distribution of baseline concentrations of
excluded analytes.
(DOCX)
Table S3 Characteristics of study participants entering
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Table S4 Differences in inflammatory profile in PTB
patients of African vs. Eurasian ancestry after comple-
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